Barely Significant
← all excerpts

A phase 2A/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD.

Alzheimers Dement · 2025 · PMC12504051 · PMID 41057918

Europe PMCDOI
1
hedged sentence
0.1000
closest p · 2.0× alpha
0.1000
boldest claim

The sentences

nominally significantp < 0.10so close (0.05 < p ≤ 0.1)
3.3 Secondary outcomes Analyses for secondary outcomes were pre‐specified; however, given the fact that the trial was not powered to detect a difference in these outcomes and no corrections were made for multiple comparisons, all effects with p < 0.05 are considered nominally significant, and effects p < 0.10 but ≥ 0.05 are considered trends.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.